- •We describe the larger series of clinical cases (n = 14) with HD-like phenotype and IAs published to date.
- •MRI and FDG-PET neuroimaging findings compatible with HD can be found in some patients with IA.
- •Larger and more detailed series are needed to assess the pathogenic role of IAs in HTT gene.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Nonmotor symptoms in Huntington disease.Int. Rev. Neurobiol. 2017; 134: 1397-1408
- Cognitive impairment in Huntington disease: diagnosis and treatment.Curr. Neurol. Neurosci. Rep. 2011; 11: 474-483
- Intermediate alleles of Huntington’s disease HTT gene in different populations worldwide: a systematic review.Genet. Mol. Res. 2017; 16
- Prevalence of carriers of intermediate and pathological polyglutamine disease-associated alleles among large population-based cohorts.JAMA Neurol. 2019; 76: 650-656
- Late onset Huntington’s disease - a differential diagnosis of Alzheimer’s disease.Nervenarzt. 2002; 73: 870-873
- Pathogenic Huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis.Neuron. 2021 Feb 3; 109 (e4): 448-460
- Clinical manifestations of intermediate allele carriers in Huntington disease.Neurology. 2016; 87: 571-578
- Huntington’s disease as caused by 34 CAG repeats.Mov. Disord. 2008; 23: 879-881
- Late-onset Huntington disease with intermediate CAG repeats: true or false?.J. Neurol. Neurosurg. Psychiatry. 2010; 81: 228-230
- Exploring the correlates of intermediate CAG repeats in Huntington disease.Postgrad. Med. 2011; 123 (116–2)
- Huntington disease in subjects from an Israeli Karaite community carrying alleles of intermediate and expanded CAG repeats in the HTT gene: Huntington disease or phenocopy?.J. Neurol. Sci. 2009; 277: 143-146
- Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.Neurology. 2013; 80: 2022-2027
- Autopsy-proven Huntington’s disease with 29 trinucleotide repeats.Mov. Disord. 2007 Jan; 22: 127-130
- Clinical phenotype in carriers of intermediate alleles in the huntingtin gene.J. Neurol. Sci. 2019; 402: 57-61
- Iron accumulation in the basal ganglia in Huntington’s disease: cross-sectional data from the IMAGE-HD study.J. Neurol. Neurosurg. Psychiatry. 2016; 87: 545-549
- MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer’s and Huntingon’s disease.Cell. Mol. Biol. (Noisy-le-grand). 2000; 46: 821-833
- Iron dysregulation in Huntington’s disease.J. Neurochem. 2014; 130: 328-350
- Increased basal ganglia iron levels in Huntington disease.Arch. Neurol. 1999; 56: 569-574
- MRI T2 Hypointensities in basal ganglia of premanifest Huntington’s disease.PLoS Curr. 2010; 2RRN1173
- Quantitative susceptibility mapping suggests altered brain iron in premanifest Huntington disease.AJNR Am. J. Neuroradiol. 2016; 37: 789-796
- Elevated brain iron is independent from atrophy in Huntington’s disease.Neuroimage. 2012; 61: 558-564
- Current status of PET imaging in Huntington’s disease.Eur. J. Nucl. Med. Mol. Imaging. 2016; 43: 1171-1182
- Metabolic network abnormalities in early Huntington’s disease: an [(18)F]FDG PET study.J. Nucl. Med. 2001; 42: 1591-1595